⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
PFIZER - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | PFIZER | Market Cap | 22,045 Cr. | Current Price | 4,823 ₹ | High / Low | 5,993 ₹ |
| Stock P/E | 29.0 | Book Value | 841 ₹ | Dividend Yield | 0.73 % | ROCE | 21.6 % |
| ROE | 16.4 % | Face Value | 10.0 ₹ | DMA 50 | 4,869 ₹ | DMA 200 | 4,976 ₹ |
| Chg in FII Hold | 0.11 % | Chg in DII Hold | -0.06 % | PAT Qtr | 182 Cr. | PAT Prev Qtr | 189 Cr. |
| RSI | 48.8 | MACD | -46.1 | Volume | 13,644 | Avg Vol 1Wk | 41,280 |
| Low price | 3,701 ₹ | High price | 5,993 ₹ | PEG Ratio | 18.3 | Debt to equity | 0.01 |
| 52w Index | 49.0 % | Qtr Profit Var | 43.0 % | EPS | 187 ₹ | Industry PE | 27.6 |
📊 Financial Overview
- Revenue & Profitability: Quarterly PAT at ₹182 Cr. vs ₹189 Cr. shows slight decline. ROE (16.4%) and ROCE (21.6%) are strong, reflecting efficient capital use and profitability.
- Debt & Liquidity: Debt-to-equity at 0.01 indicates negligible leverage, ensuring strong balance sheet stability.
- Valuation: P/E of 29.0 is slightly above industry average (27.6), suggesting fair valuation. P/B ~5.7 indicates premium pricing relative to book value. PEG ratio (18.3) highlights expensive growth expectations.
- Technical Indicators: RSI at 48.8 shows neutral momentum; MACD at -46.1 indicates bearish trend. Current price ₹4,823 is below DMA 50 (₹4,869) and DMA 200 (₹4,976), signaling weakness.
🏢 Business Model & Competitive Advantage
- Pfizer India operates in pharmaceuticals, focusing on innovative medicines, vaccines, and healthcare solutions.
- Competitive advantage lies in strong global brand, R&D capabilities, and diversified product portfolio.
💡 Entry Zone Recommendation
- Entry zone: ₹4,700–₹4,850, near support levels.
- Attractive for long-term investors given strong fundamentals, but caution advised due to high PEG ratio and bearish technicals.
📈 Long-Term Holding Guidance
- Suitable for long-term holding due to strong ROE/ROCE and global brand strength.
- Upside potential tied to pharmaceutical demand, vaccine innovation, and healthcare expansion in India.
✅ Positive
- Strong ROE (16.4%) and ROCE (21.6%).
- Low debt-to-equity ratio (0.01).
- Dividend yield of 0.73% adds investor appeal.
- FII holdings increased (+0.11%).
⚠️ Limitation
- PEG ratio (18.3) indicates expensive growth expectations.
- P/B ratio (~5.7) shows premium valuation.
- Stock trading below DMA 50 and DMA 200, showing bearish trend.
📉 Company Negative News
- Quarterly PAT declined slightly from ₹189 Cr. to ₹182 Cr.
- Bearish technical indicators (MACD negative, price below DMA).
- DII holdings reduced (-0.06%).
📈 Company Positive News
- FII holdings increased (+0.11%).
- Strong efficiency metrics (ROE/ROCE).
- 52-week index gain of 49% shows investor confidence.
🏭 Industry
- Pharmaceutical industry P/E at 27.6, slightly lower than Pfizer India’s valuation.
- Sector growth driven by rising healthcare demand, vaccine innovation, and global pharmaceutical expansion.
🔎 Conclusion
- Pfizer India is fundamentally strong with efficient returns, low debt, and global brand advantage but trades at a valuation premium.
- Entry near ₹4,700–₹4,850 is attractive for long-term investors; recommended as a cautious holding with potential upside tied to healthcare sector growth.